NextCure Inc (NAS:NXTC)
$ 1.38 -0.05 (-3.5%) Market Cap: 38.60 Mil Enterprise Value: -40.84 Mil PE Ratio: 0 PB Ratio: 0.45 GF Score: 39/100

NextCure Inc Updated Clinical Data from NC318 Phase 1/2 Clinical Trial Presentation Transcript

Nov 09, 2019 / 11:30PM GMT
Michael Richman
NextCure - President and Chief Executive Officer

Presentation
Nov 09, 2019 / 11:30PM GMT

=====================
Corporate Participants
=====================
* Michael Richman
NextCure - President and Chief Executive Officer
* Kevin Heller
NextCure - Chief Medical Officer

=====================
Conference Call Participants
=====================
* Jeffrey Hung
Morgan Stanley - Analyst
* Chad Messer
Needham & Company - Analyst
* Alec Stranahan
Bank of America Merrill Lynch - Analyst

=====================
-

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot